» Articles » PMID: 35162468

Recommendations on Weight Loss and Healthy Lifestyle in Prostate Cancer Clinical Guidelines: A Systematic Review

Overview
Publisher MDPI
Date 2022 Feb 15
PMID 35162468
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is associated with negative prostate cancer outcomes (e.g., specific mortality, all-cause mortality, biochemical recurrence, etc.), according to the current scientific literature. Nevertheless, recommendations on weight loss and healthy lifestyles are poorly covered by clinicians. We aimed at identifying these recommendations from clinical practice guidelines (CPGs) for prostate cancer. We systematically searched MEDLINE, EMBASE, Web of Science, Scopus, guideline databases and online sources for CPGs updated from January 2015 to August 2021. The searches were independently conducted by two researchers, without language restrictions. A total of 97 prostate cancer guidelines, including 84 (86.6%) CPGs and 13 (13.4%) consensus statements, were included. Recommendations on reaching and maintaining a healthy weight or healthy lifestyles were provided by 7 (7.2%) and 13 (13.4%) documents, respectively. No differences regarding recommendations were found by type of document, year of publication or country. Our results suggest that professional societies and governments should update prostate cancer guidelines to include these recommendations for improving prostate cancer prognosis.

Citing Articles

PC-PEP, a Comprehensive Daily Six-Month Home-Based Patient Empowerment Program Leads to Weight Loss in Men with Prostate Cancer: A Secondary Analysis of a Clinical Trial.

MacNevin W, Ilie G, Rendon R, Mason R, Spooner J, Chedrawe E Curr Oncol. 2024; 31(3):1667-1688.

PMID: 38534960 PMC: 10969418. DOI: 10.3390/curroncol31030127.


Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment.

Cuttica C, Briata I, DeCensi A Nutrients. 2023; 15(17).

PMID: 37686769 PMC: 10490004. DOI: 10.3390/nu15173737.


Developing a Core Outcome Set for Assessing Clinical Safety Outcomes of Prostate Cancer in Clinical Trials of Traditional Chinese Medicine: Protocol for a Mixed Methods Study.

Tian H, Zhang Y, Ren J, Wang C, Mou R, Li X JMIR Res Protoc. 2023; 12:e46794.

PMID: 37549007 PMC: 10442731. DOI: 10.2196/46794.

References
1.
Saad F, Aprikian A, Finelli A, Fleshner N, Gleave M, Kapoor A . 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2021; 15(2):E81-E90. PMC: 7864710. DOI: 10.5489/cuaj.7074. View

2.
Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J . Impact of obesity upon prostate cancer-associated mortality: A meta-analysis of 17 cohort studies. Oncol Lett. 2015; 9(3):1307-1312. PMC: 4315023. DOI: 10.3892/ol.2014.2841. View

3.
van Rooijen S, Carli F, Dalton S, Thomas G, Bojesen R, Le Guen M . Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation. BMC Cancer. 2019; 19(1):98. PMC: 6341758. DOI: 10.1186/s12885-018-5232-6. View

4.
Pisansky T, Thompson I, Valicenti R, DAmico A, Selvarajah S . Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019. J Urol. 2019; 202(3):533-538. PMC: 8680266. DOI: 10.1097/JU.0000000000000295. View

5.
Freedland S, Allen J, Jarman A, Oyekunle T, Armstrong A, Moul J . A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). Clin Cancer Res. 2020; 26(12):3035-3043. DOI: 10.1158/1078-0432.CCR-19-3873. View